Business Context and Reporting Period
This Form 8-K, filed on July 18, 2011, reports that AMHN, Inc. (a Nevada corporation) entered into an Agreement and Plan of Merger to acquire 100% of VitaMedMD, LLC ("VitaMed"). VitaMed is a specialty pharmaceutical company focused on prescription and OTC nutrition and medical foods, utilizing a patent-pending IT platform to improve patient compliance and reduce distribution costs. The transaction involves a reverse stock split, a name change to TherapeuticsMD, Inc., and a complete change in board composition.
Key Financial Metrics
The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for either AMHN, Inc. or VitaMedMD, LLC. This report focuses exclusively on the terms of the merger agreement rather than historical financial performance.
Material Changes and Transaction Terms
- Merger Structure: AMHN, Inc. will acquire VitaMed via a merger with a wholly-owned subsidiary, VitaMed Acquisition, LLC.
- Corporate Actions: Prior to closing, AMHN will execute a 1-for-100 reverse stock split, increase authorized common stock to 250,000,000 shares, and amend its Long Term Incentive Compensation Plan.
- Share Issuance: All outstanding VitaMed membership units, options, and warrants will be converted into approximately 70,000,000 shares of the Company's Common Stock.
- Ownership Structure: Post-transaction, VitaMed members will own approximately 99% of the approximately 58,934,800 shares outstanding.
- Lock-Up: All shares issued in exchange for VitaMed interests are subject to an 18-month lock-up agreement.
- Management Change: The existing sole director and officer of AMHN will resign, and VitaMed-designated persons will be appointed to the Board of Directors.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statement disclaimers, noting that actual results may differ materially from expectations due to various factors. The company does not undertake an obligation to update these statements. The primary risk highlighted is the uncertainty of the merger's completion and the potential for representations and warranties in the agreement to differ from actual facts due to confidential disclosure schedules and materiality standards.
Investor Verification Checklist
- Verify the final approval of the merger by the Company's majority shareholder.
- Confirm the filing of the Certificate of Merger with the Delaware Secretary of State to establish the Effective Time.
- Review the full text of the Agreement and Plan of Merger (Exhibit 10.01) for specific representations, warranties, and covenants.
- Monitor the execution of the 1-for-100 reverse stock split and the subsequent name change to TherapeuticsMD, Inc.
- Assess the financial health and valuation of VitaMedMD, LLC, as no financial data is provided in this filing.